Roche rounds off SUNFISH study with evidence of Evrysdi’s long-term efficacy

17 March 2025

The Roche (ROG: SIX) subsidiary Genentech has presented five-year SUNFISH data on Evrysdi (risdiplam) in the final readout of this pivotal study.

These data support the drug’s longer-term efficacy and safety for people with types two and three spinal muscular atrophy (SMA), who are aged two to 25 years at enrollment.

Evrysdi demonstrated long-term stabilization of motor function improvements from baseline that were observed during the first year, as measured by motor function measure 32.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK